Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ATOS

Atossa Therapeutics Inc

Apr 16 • 02:11PM ET

1.57

Dollar change -0.14
Percentage change -8.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	0.04%	Shs Outstand	125.30M	Perf Week	-14.67%
Market Cap	196.72M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-33.28%	Shs Float	125.25M	Perf Month	21.71%
Income	-30.09M	PEG	-	EPS next Q	-0.07	Inst Own	19.14%	Short Float	8.43%	Perf Quarter	83.56%
Sales	0.00M	P/S	-	EPS this Y	-13.89%	Inst Trans	-14.05%	Short Ratio	7.12	Perf Half Y	137.84%
Book/sh	0.73	P/B	2.16	EPS next Y	-8.54%	ROA	-27.38%	Short Interest	10.56M	Perf Year	113.61%
Cash/sh	0.71	P/C	2.22	EPS next 5Y	-	ROE	-28.80%	52W Range	0.59 - 2.31	Perf YTD	78.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.61%	ROI	-33.06%	52W High	-32.03%	Beta	1.25
Dividend TTM	-	Quick Ratio	17.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	166.06%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	17.61	EPS Y/Y TTM	-12.07%	Oper. Margin	0.00%	RSI (14)	47.80	Volatility	9.66% 13.72%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-4.56%	Payout	-	Rel Volume	0.89	Prev Close	1.71
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Apr 01 AMC	Avg Volume	1.48M	Price	1.57
SMA20	-11.44%	SMA50	18.00%	SMA200	61.54%	Trades		Volume	972,030	Change	-8.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-18	Initiated	Maxim Group	Buy	$2

Apr-15-24 08:30AM	Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Apr-11-24 10:10AM	Atossa (ATOS) Reports Positive Results From EVANGELINE Study (Zacks)
08:30AM	Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference (GlobeNewswire)
Apr-09-24 11:59AM	Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen (GlobeNewswire) +5.14%
Apr-01-24 10:53PM	ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.11%
04:00PM	Loading…
04:00PM	Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient (GlobeNewswire) +20.16%
Mar-18-24 08:30AM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire)
Mar-12-24 08:30AM	Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors (GlobeNewswire) +9.17%
Mar-06-24 08:30AM	Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +12.75%
Feb-22-24 08:30AM	Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study (GlobeNewswire)
Feb-07-24 08:30AM	Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial (GlobeNewswire) +5.84%
Jan-09-24 08:30AM	Atossa Therapeutics Issues Letter to Shareholders (GlobeNewswire)
Dec-18-23 09:00AM	Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus (PR Newswire)
Dec-08-23 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Loading…
Dec-04-23 08:30AM	Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director (GlobeNewswire)
Nov-20-23 08:30AM	Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire) +8.82%
Nov-13-23 09:00AM	Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-23 09:00AM	Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors (GlobeNewswire) -6.49%
Oct-30-23 01:00PM	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group (PR Newswire)
Oct-11-23 08:30AM	Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later (PR Newswire)
Sep-18-23 09:25AM	Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment (ACCESSWIRE)
08:30AM	Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Aug-23-23 08:00AM	Atossa Therapeutics backing Endoxifen in the fight against breast cancer (News Direct)
Aug-14-23 08:30AM	Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.29%
Aug-08-23 09:00AM	Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023 (GlobeNewswire)
Jul-20-23 09:15AM	Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada (GlobeNewswire) +6.54%
Jul-13-23 04:15PM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire) -10.37%
Jul-12-23 09:00AM	50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis (ACCESSWIRE) +6.30%
Jul-10-23 09:15AM	Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
09:28PM	Loading…
Jul-06-23 09:28PM	3 Penny Stocks to Make Your Get Rich Dreams Come True (InvestorPlace)
09:15AM	Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer (GlobeNewswire)
Jun-28-23 01:03PM	Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial (News Direct) +22.51%
09:15AM	Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial (GlobeNewswire)
Jun-27-23 09:15AM	Atossa Therapeutics Announces $10M Stock Repurchase Program (GlobeNewswire) +8.50%
Jun-22-23 04:15PM	Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023 (GlobeNewswire)
Jun-21-23 01:48PM	Atossa Therapeutics announces further patent protection for Endoxifen (News Direct)
10:13AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Jun-14-23 09:15AM	Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC (GlobeNewswire)
Jun-12-23 09:15AM	Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire)
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
May-23-23 07:00AM	Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator (GlobeNewswire) +15.02%
May-15-23 09:10AM	Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-23 09:00AM	Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices (PR Newswire)
May-09-23 09:15AM	Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-27-23 09:15AM	Atossa Therapeutics to Participate in Tribe Publics Webinar Event Redefining Breast Cancer Prevention and Treatment (GlobeNewswire)
Mar-30-23 11:00AM	We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate (Simply Wall St.)
Mar-22-23 04:05PM	Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.30%
Mar-21-23 01:19PM	Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial (PR Newswire)
Mar-15-23 09:25AM	Atossa to Present at the Sidoti Small-Cap Virtual Conference (GlobeNewswire)
Feb-23-23 09:15AM	Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Feb-13-23 09:15AM	Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen (GlobeNewswire) +10.30%
Jan-25-23 09:15AM	Atossa Therapeutics Issues Letter to Shareholders (GlobeNewswire) +10.91%
Dec-07-22 08:00AM	Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations (GlobeNewswire) -6.85%
Nov-07-22 04:00PM	Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-22 09:15AM	Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy (GlobeNewswire) -6.05%
Oct-25-22 09:15AM	Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D. (GlobeNewswire) +6.15%
Oct-24-22 09:15AM	Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Oct-21-22 10:26AM	Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation (Simply Wall St.)
Sep-07-22 09:00AM	Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-22-22 09:30AM	Registration Now Open for Tribe Publics Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022 (GlobeNewswire)
Aug-18-22 09:30AM	Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board (GlobeNewswire)
Aug-08-22 04:30PM	Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-22 09:00AM	Dosing Completed in Part C of Atossas Phase 1/2a Study of AT-H201 in Healthy Volunteers (GlobeNewswire)
Jul-13-22 06:56PM	Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst (TipRanks)
Jul-11-22 05:25PM	Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company (American City Business Journals)
Jun-02-22 04:05PM	Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations (GlobeNewswire)
May-18-22 09:30AM	Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference (GlobeNewswire) -5.25%
May-14-22 08:55AM	Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-09-22 04:05PM	Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-27-22 09:30AM	Atossa Therapeutics to Present at the Q2 Investor Summit Conference (GlobeNewswire) +15.03%
Apr-20-22 09:30AM	Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201 (GlobeNewswire) +5.50%
Mar-23-22 09:30AM	Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire) -5.77%
Mar-08-22 09:15AM	Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen (GlobeNewswire)
Feb-28-22 04:15PM	Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-22 05:30AM	The Olympics Business Model: Why Multi-Year Media Deals Matter (WSJ)
Jan-27-22 09:30AM	Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022 (GlobeNewswire)
Jan-18-22 09:30AM	Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201 (GlobeNewswire)
Dec-22-21 09:30AM	Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden (GlobeNewswire)
Dec-16-21 09:00AM	Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur (PR Newswire)
Dec-06-21 09:15AM	Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration (GlobeNewswire)
Dec-05-21 06:38AM	Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-24-21 09:30AM	Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 A Town Hall Q&A Event With Atossa Therapeutics Management Team (GlobeNewswire)
Nov-15-21 09:30AM	Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-21-21 09:30AM	Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month (GlobeNewswire)
Sep-30-21 09:30AM	Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia (GlobeNewswire)
Sep-13-21 05:47PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS (Newsfile) -11.84%
Sep-10-21 01:48PM	3 Reasons to Love Atossa Therapeutics Stock (TipRanks) +8.47%
Sep-07-21 05:20PM	Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote (GlobeNewswire)
Sep-02-21 09:30AM	Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden (GlobeNewswire)
Aug-25-21 04:11PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS (Newsfile)
Aug-13-21 09:30AM	Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting (GlobeNewswire)
Aug-05-21 09:30AM	Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021 (GlobeNewswire) +5.71%
Jul-15-21 09:00AM	Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress (PR Newswire) -11.50%
Jul-09-21 10:54AM	Atossas COVID-19 Treatment Has Potential, Says Analyst (TipRanks)
Jul-07-21 09:30AM	Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia (GlobeNewswire)
Jun-16-21 09:00AM	Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-14-21 06:13PM	Time to Load up on Atossa Shares? This Analyst Thinks So (TipRanks) +7.19%
Jun-11-21 09:00AM	Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density (GlobeNewswire) +5.90%
Jun-09-21 09:00AM	Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated (GlobeNewswire) -27.51%

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Finn Jonathan	Director	Apr 10 '24	Buy	1.77	25,000	44,250	25,000	Apr 11 04:05 PM
WEAVER GREGORY L	Former EVP, CFO, & Director	Nov 15 '23	Sale	0.65	50,000	32,500	55	Nov 17 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATOS

Atossa Therapeutics Inc

Upgrade your FINVIZ experience